6-Adenine and 2-Guanine Benzenesulphonamide: Synthesis and In silico anticancer properties.

Abstract

Sulphonamide preparation converts readily available aromatic amines into life-saving anticancer molecules. Many drugs available for the cure of cancer are no longer active due to drug resistance. Novel derivatives of adenine and guanine incorporating benzenesulphonamide have been synthesized, characterized and investigated for in silico anti-cancer properties. The reaction of adenine and guanine with benzenesulphonyl chloride afforded N-(9H-purin-6- yl)benzenesulphonamide (4) and N-(6-dihydro-1H-purin-2-yl)benzenesulphonamide (6) respectively in 66% and 42% yields. The compounds were characterized using Ultra-violet visible and FTIR techniques. The compounds were assayed for their in silico anticancer activities using their binding energies with hormone-bound human progesterone receptor ligand binding domain (1A28), estrogen receptor alpha ligand-binding domain (1A52), epidermal growth factor tyrosine kinase (1M17) and human androgen receptor (1E3G). Diclofenac was used as the standard drug.The ligand s-protein complex showed binding energies ranges between -8.0 to - 5.9. The highest and lowest binding energies were -8.0 and -5.0 recorded in the (1A28-4) complex and (diclofenac-1A52) complex respectively. All the compounds showed good binding energies comparable to the standard drug diclofenac.